StockWatch
·

Transrail Lighting Ltd Q2 FY27 Results

TRANSRAILLQ2 FY27 Results
Filing
Result:Good· Market: Up#Margin squeeze

Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue2.1K18.4%31.7%
Total Income2.1K18.1%31.4%
Expenditure1.9K18.9%31.7%
PBT156.899.2%27.8%
Net Profit103.943.6%14.2%
OPM11.51%0.14pp0.27pp
NPM5.02%1.14pp0.76pp
EPS7.743.7%14.2%
View full financials

Strong 31.7% revenue growth for the EPC/industrials business, but OPM and NPM both contracted YoY causing PAT growth (14.2%) to lag well behind top-line, capping this at good rather than very_good.

TRANSRAIL LIGHTING · Q2 FY27 · THE VERDICT

32% Revenue Growth, Profits Stuck in Traffic — and Why the Market Bolted

Transrail delivered a headline beat on revenue (31.7% YoY vs. prior 20% guidance) and order book momentum, but profit growth lagged badly (PAT up 14% YoY despite revenue +32%). Depreciation from capex is eating the margin — and the stock has already priced in the doubt.

11 Nov 2026 · 6 min read
Revenue

₹2,056 Cr

+31.7% YoY, +18.4% QoQ

PAT

₹104 Cr

+14.2% YoY, -3.7% QoQ

EBITDA margin

11.6%

vs 11%+ guidance (met)

PAT margin

5.0%

vs 5.4% Q1 est. (compressed)

The numbers tell two stories. Revenue surged 32% — a beat on the prior 20% full-year guidance — and EBITDA margin held at 11.6%, meeting the 11%+ target. But profit growth flatlined relative to the top line. PAT grew 14% YoY in a quarter when revenue grew 32%. More telling: QoQ, revenue jumped 18% while PAT fell 4%. This is a capex depreciation story, not a demand or pricing story.

The profit leak: depreciation up 35%, interest rising

Management disclosed the root cause on the call without hedging. Depreciation surged 35% year-on-year because of capacity expansion capex (tower and conductor manufacturing facilities now coming onto the books). Interest costs are also rising in absolute terms as the company finances the ₹3,900 crore solar IPP (990 MW) and core T&D capex. The math: EBITDA +28% YoY, but after depreciation and interest, PAT grew only 14%. This gap is structural, not temporary — it will persist until depreciation costs amortize over the full capex cycle.

The company guided PAT margin at 5.5–6% going forward. That is effectively below Q2's 5.0% delivery (or at best level with it), signaling management expects continued near-term margin pressure. For a company posting +32% revenue growth, margin guidance that doesn't hint at upside recovery is candid about execution headwinds.

Management's claims — what holds up

Earnings call assertions graded against delivered results

Q2 revenue ₹2,056 Cr, 32% YoY growth

₹2,056.3 Cr, 31.7% YoY

Supported

EBITDA margin 11%+ maintained

11.6% delivered

Supported

20% YoY growth for next 3 years (FY27–29)

Q2 beat prior 20% guidance at 31.7%; order book ₹14.2K Cr underpins visibility

Supported

PAT margin 5.5–6% going forward

Q2 delivered 5.0%; Q1 est. 5.4%. Guidance level-to-slightly-up implies continued pressure

Credible but signals no recovery near-term

INR10,000+ Cr annual order intake achievable

Already ₹3,500 Cr in H1; bidding pipeline ₹30,000+ Cr at 10–12% historical win ratio

Supported; high confidence

What changed: order book, capacity, and new segments

Order book visibility deepened. As of quarter-end, the order backlog stood at ₹14,218 crore — up 27% from an implied ₹11,200 crore at Q1 end. Post-quarter announcements added ₹1,747 crore, lifting prospective visibility to ₹16,000 crore (roughly 6–8 quarters of run-rate at current volumes). This is concrete: large HTLS re-conductoring wins (₹770 crore in 5 jobs), greenfield GIS transmission in Jordan, and recurring pipeline orders.

Capacity roadmap accelerated on schedule. Tower manufacturing capacity expanded to 1.84 lakh metric tons per annum (target 2 lakh tons by end FY27, a +9% stretch). Conductor capacity now 40,800 km p.a., with a guided target of 49,500 km (+21% by year-end). Phase 1 of the conductor expansion was completed ahead of schedule — a credibility mark for execution. Backward integration (own tower and HTLS conductor production with Epsilon, a French partner supplying carbon cores) reduces supply chain risk and cost.

Two new segments materialized. HTLS re-conductoring (high-temperature low-sag conductors) is a margin uplift opportunity — the company won ₹770 crore in orders in Q2 with technology partner Epsilon. This is adjacent to core transmission towers but offers higher margins and insulates the company from commoditized tower competition. The solar IPP (49% stake in a 990 MW Maharashtra project) represents a ₹3,900 crore capex commitment, with revenue entry guided for FY28 onwards. Fixed-tariff recurring revenue; no volume or price risk once operational.

The bull-bear ledger
  • Revenue beat prior guidance (31.7% vs. 20% FY27 target)

  • Order book visibility strong (₹14.2K Cr, 6–8Q run-rate)

  • Capacity ramp on schedule; backward integration reduces supply risk

  • New HTLS and solar segments diversify and lift long-term ceiling

  • Operating cash flow strong (H1 ₹435 Cr vs. ₹29 Cr prior year)

  • PAT margin compression is real: 5.4% Q1 → 5.0% Q2 despite revenue +18% QoQ

  • Depreciation +35% YoY will persist until capex cycle matures (24–36m)

  • Profit margin guidance (5.5–6%) below organic expectation; no near-term recovery signaled

  • Solar IPP revenue (FY28) and international traction (US, Australia) unproven

  • Stock down 49% from ATH; institutional ownership (FII 2.49%) low and declining

Street positioning — why the stock crashed

Transrail trades at ₹439.5 as of November 9, 2026 — down 48.6% from its all-time high of ₹855.8. The stock sits below its 20-day (₹446.4), 50-day (₹445.0), and 200-day (₹496.7) moving averages, signaling a sustained downtrend. RSI at 47 (neutral) suggests no oversold bounce imminent. Volume is normal, not panic-driven; this is a grinding re-rating, not a capitulation.

Institutional positioning reinforces skepticism. FII ownership rose marginally to 2.49% (up 33 bps QoQ), but the absolute level is anemic for a ₹30,000+ crore bidding pipeline franchise. DII holdings dropped 163 bps to 6.52%, the lowest in the data series — institutional India is trimming, not loading. Recent bulk block deals show mixed signals: QE Securities bought 7.29 lakh shares at ₹467.93 but also sold 7.56 lakh shares at ₹465.81 (flat-price reversals); Microcurves Trading bought 10.1 lakh shares at ₹473.07 then sold the same quantity at ₹473.41 (scalping, not accumulation). No insider or promoter buying is visible. The message: even buyers are treating this as a trade, not a conviction hold.

The crash makes sense through a near-term lens. Investors expected 32% revenue growth to deliver outsized PAT growth; instead, profit lagged at +14% YoY. Margin guidance that doesn't promise recovery is a sell signal when the stock had priced in a cyclical inflection. The market has already discounted the capex depreciation drag and is pricing execution risk (solar IPP, HTLS, international) at a premium. A 49% drawdown from ATH is a real loss, but it also suggests the street has reset expectations to a more cautious baseline.

Risks, ranked by concern

What can go wrong — and how much it matters to a holder

Margin recovery delayed beyond 24–36 months

High

PAT margin guidance (5.5–6%) below current 5.0% signals no near-term recovery. If capex depreciation persists longer (project delays, extended amortization), margin upside is pushed further out. Investors priced in recovery; delay = re-rating downside.

Solar IPP revenue entry slips beyond FY28

High

CFO guided ₹400–500 crore+ revenue entry for FY28, representing 2% of prospective revenue but critical for diversification narrative. Project commissioning delays (common in 990 MW solar) would defer 4–8 quarters and dent credibility of '3-year 20% growth' target.

HTLS re-conductoring orders don't scale beyond ₹770 Cr

Medium

₹770 crore in awarded HTLS jobs is positioned as a margin uplift and new segment. But this is a small absolute base and unproven scalability. If win rate drops or margin profile doesn't materialize, a key bull thesis (margin recovery from product mix) evaporates.

International expansion traction remains nil (US, Australia, Jordan)

Medium

Management targets 60–40 domestic-international split by FY29. Today it's ~60–40 but international is all domestic-adjacent (Jordan greenfield GIS, Australia seed orders). If international orders don't scale or margins compress in competitive bids, the growth ceiling lowers.

Input cost inflation (aluminum, copper, steel) uncontained

Medium

Management hedges commodity inputs for FY27 but acknowledged inflation is 'marginally coming down.' If labor/steel costs spike and hedges roll off, margin guidance (5.5–6%) will be tested.

Order book ₹14.2K Cr concentrated with 2–3 anchor customers

Low-Medium

Granular customer mix not disclosed. Large transmission/distribution orders can be lumpy; loss of a key customer or project delay would dent revenue visibility.

Share pledge and QIP dilution ahead

Low

Promoter share pledge (2–3% of capital) is due for redemption in 6–9 months; QIP for BESS/data center capex unfinalized. Dilution is manageable but adds noise.

What to watch next

Three concrete catalysts that resolve the bull-bear debate
  • 1 · Q3–Q4 FY27: Capacity ramp completion and order book conversion

    Target completion of tower capacity expansion to 2 lakh tons and conductor to 49,500 km by end FY27. Visible order backlog ₹14.2K Cr provides demand; watch for project execution delays (slippage would push revenue into FY28). Q3–Q4 margins matter: if depreciation momentum eases as capex tapers, profit growth should re-accelerate relative to revenue.

  • 2 · FY28 H1: Solar IPP and HTLS revenue ramp

    Solar IPP entry guided for FY28 onwards with ₹400–500 crore+ recurring revenue expected. HTLS re-conductoring (₹770 Cr awarded) should begin revenue recognition in FY28. Watch for project commissioning timeline (common risk in solar), margin profile delivery on HTLS, and order win ratio on new 5-conductor jobs. These two segments are critical to the 'margin recovery' thesis.

  • 3 · PAT margin trajectory (near term vs. forward guidance)

    The core debate. Management guided 5.5–6% PAT margin going forward, but Q2 delivered 5.0% (below the guidance band). Watch Q3–Q4 for whether margins approach the 5.5% lower bound (easing depreciation, operational leverage) or stay anchored at 5.0–5.2% (persistent capex drag, interest cost pressure). If margin stays below 5.5% through FY27-end, the 'capex cycle takes 36+ months to amortize' bear case gains credibility.

The honest read

Transrail is executing well operationally. Revenue beat guidance, order book momentum is real, capacity is ramping ahead of schedule, and the company is prudently diversifying (HTLS, solar, exports). This is not a franchise in trouble.

But near-term profit growth will disappoint relative to headline numbers because depreciation and interest are large, real, and structural. Management acknowledged this by guiding PAT margin flat-to-slightly-up (5.5–6% forward, vs. 5.0% Q2 delivery), which is effectively a reality check. For investors expecting profit to decelerate no more than revenue, the quarter is a letdown.

The bull case — 20% multi-year growth with margin recovery — is 24–36 months out. The bear case — margins stay pinned below 5.5% for another 4–6 quarters, delaying capex ROI realization — is plausible and priced in by the market (stock down 49% from ATH). The stock's 49% drawdown is a real market judgment that this is a steady execution story, not a step-change growth inflection. Until margins trend visibly toward the 5.5–6% band (probably not until late FY27 or FY28), institutional investors will remain cautious.

For a holder or entrant, the number to track from here is the PAT margin trajectory through Q3–Q4 FY27. If margins hold at 5.0–5.2%, the capex drag is more durable than management implies. If margins push above 5.4%, the recovery thesis gains traction and the 49% drawdown becomes a re-entry opportunity. That's the pivot.

Transrail delivered a solid operational quarter: 32% revenue growth, order book up 27%, capacity ramp on track. But the margin lag — profit growth only 14% YoY despite revenue +32%, with PAT falling 4% QoQ — is the real story. Depreciation and interest are eating profits in the short term. Management's flat-to-up margin guidance (5.5–6% forward) is credible but signals no near-term recovery. The market's 49% drawdown reflects this skepticism. The stock is a 24–36 month conviction hold (when capex amortization eases), not a near-term trade. Watch the PAT margin trend through FY27-end to validate or disprove the recovery thesis.

Informational and educational content only. Not investment advice.